Company profile
THERAVANCE BIOPHARMA, INC.
NASDAQ:TBPHBiotechnology: Pharmaceutical Preparations
Drug pipeline (7)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VIBATIV | approved | — | 0 | — |
| AMPRELOXETINE | phase3 | — | 9 | active |
| CEFILAVANCIN | phase2 | — | 1 | no active trials |
| IZENCITINIB | phase2 | — | 4 | completed, terminated |
| NEZULCITINIB | phase2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (46)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02663089 | phase1 | completed | 2016-02-08 | 2016-03-17 | Theravance Biopharma | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects |
| NCT01644240 | phase1 | terminated | 2012-09-01 | 2012-11-01 | Theravance Biopharma | A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects |
| NCT01458340 | phase2 | completed | 2011-12-01 | 2013-10-01 | Theravance Biopharma | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| NCT00687700 | phase1 | completed | 2008-03-10 | 2008-05-27 | Theravance Biopharma | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers |
| NCT00674817 | phase2 | completed | 2008-04-01 | 2008-10-01 | Theravance Biopharma | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 022407 | — | NDA | THERAVANCE INC | |||||
Loading… | ||||||||